Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis

<strong>Background:</strong> Artemisinin resistance in Plasmodium falciparum manifests as slow parasite clearance but this measure is also influenced by host immunity, initial parasite biomass and partner drug efficacy. This study collated data from clinical trials of artemisinin derivat...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Abdulla, S, Ashley, E, Bassat, Q, Bethell, D, Bjorkman, A, Borrmann, S, D'Alessandro, U, Dahal, P, Day, N, Diakite, M, Djimde, A, Dondorp, A, Duong, S, Edstein, MD, Fairhurst, R, Faiz, M, Falade, C, Flegg, J, Fogg, C, Gonzalez, R, Greenwood, B, Guerin, P, Guthmann, J, Hamed, K, Hien, T, Htut, Y, Juma, E, Lim, P, Martensson, A, Mayxay, M, Mokuolu, O, Moreira, C, Newton, P, Noedl, H, Nosten, F, Ogutu, B, Onyamboko, M, Owusu-Agyei, S, Phyo, A, Premji, Z, Price, R, Pukrittayakamee, S, Ramharter, M, Sagara, I, Se, Y, Suon, S, Stepniewska, K, Ward, SA, White, N, Winstanley, P, Grp, W
বিন্যাস: Journal article
প্রকাশিত: BioMed Central 2015
_version_ 1826280032826294272
author Abdulla, S
Ashley, E
Bassat, Q
Bethell, D
Bjorkman, A
Borrmann, S
D'Alessandro, U
Dahal, P
Day, N
Diakite, M
Djimde, A
Dondorp, A
Duong, S
Edstein, MD
Fairhurst, R
Faiz, M
Falade, C
Flegg, J
Fogg, C
Gonzalez, R
Greenwood, B
Guerin, P
Guthmann, J
Hamed, K
Hien, T
Htut, Y
Juma, E
Lim, P
Martensson, A
Mayxay, M
Mokuolu, O
Moreira, C
Newton, P
Noedl, H
Nosten, F
Ogutu, B
Onyamboko, M
Owusu-Agyei, S
Phyo, A
Premji, Z
Price, R
Pukrittayakamee, S
Ramharter, M
Sagara, I
Se, Y
Suon, S
Stepniewska, K
Ward, SA
White, N
Winstanley, P
Grp, W
author_facet Abdulla, S
Ashley, E
Bassat, Q
Bethell, D
Bjorkman, A
Borrmann, S
D'Alessandro, U
Dahal, P
Day, N
Diakite, M
Djimde, A
Dondorp, A
Duong, S
Edstein, MD
Fairhurst, R
Faiz, M
Falade, C
Flegg, J
Fogg, C
Gonzalez, R
Greenwood, B
Guerin, P
Guthmann, J
Hamed, K
Hien, T
Htut, Y
Juma, E
Lim, P
Martensson, A
Mayxay, M
Mokuolu, O
Moreira, C
Newton, P
Noedl, H
Nosten, F
Ogutu, B
Onyamboko, M
Owusu-Agyei, S
Phyo, A
Premji, Z
Price, R
Pukrittayakamee, S
Ramharter, M
Sagara, I
Se, Y
Suon, S
Stepniewska, K
Ward, SA
White, N
Winstanley, P
Grp, W
author_sort Abdulla, S
collection OXFORD
description <strong>Background:</strong> Artemisinin resistance in Plasmodium falciparum manifests as slow parasite clearance but this measure is also influenced by host immunity, initial parasite biomass and partner drug efficacy. This study collated data from clinical trials of artemisinin derivatives in falciparum malaria with frequent parasite counts to provide reference parasite clearance estimates stratified by location, treatment and time, to examine host factors affecting parasite clearance, and to assess the relationships between parasite clearance and risk of recrudescence during follow-up. <strong>Methods:</strong> Data from 24 studies, conducted from 1996 to 2013, with frequent parasite counts were pooled. Parasite clearance half-life (PC 1/2 ) was estimated using the WWARN Parasite Clearance Estimator. Random effects regression models accounting for study and site heterogeneity were used to explore factors affecting PC 1/2 and risk of recrudescence within areas with reported delayed parasite clearance (western Cambodia, western Thailand after 2000, southern Vietnam, southern Myanmar) and in all other areas where parasite populations are artemisinin sensitive. <strong>Results:</strong> PC 1/2 was estimated in 6975 patients, 3288 of whom also had treatment outcomes evaluate d during 28–63 days follow-up, with 93 (2.8 %) PCR-confirmed recrudescences. In areas with artemisinin-sensitive parasites, the median PC 1/2 following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of patients with PC 1/2 &gt;5 h from 0 to 10 %. Artesunate doses of 4 mg/kg/day decreased PC 1/2 by 8.1 % (95 % CI 3.2–12.6) compared to 2 mg/kg/day, except in populations with delayed parasite clearance. PC 1/2 was longer in children and in patients with fever or anaemia at enrolment. Long PC 1/2 (HR = 2.91, 95 % CI 1.95–4.34 for twofold increase, p &lt; 0.001) and high initial parasitaemia (HR = 2.23, 95 % CI 1.44–3.45 for tenfold increase, p &lt; 0.001) were associated independently with an increased risk of recrudescence. In western Cambodia, the region with the highest prevalence of artemisinin resistance, there was no evidence for increasing PC 1/2 since 2007. <strong>Conclusions:</strong> Several factors affect PC 1/2 . As substantial heterogeneity in parasite clearance exists between locations, early detection of artemisinin resistance requires reference PC 1/2 data. Studies with frequent parasite count measurements to characterize PC 1/2 should be encouraged. In western Cambodia, where PC 1/2 values are longest, there is no evidence for recent emergence of higher levels of artemisinin resistance.
first_indexed 2024-03-07T00:07:39Z
format Journal article
id oxford-uuid:7819a64b-9c03-4f66-a9e2-e9ac58c6935a
institution University of Oxford
last_indexed 2024-03-07T00:07:39Z
publishDate 2015
publisher BioMed Central
record_format dspace
spelling oxford-uuid:7819a64b-9c03-4f66-a9e2-e9ac58c6935a2022-03-26T20:28:35ZBaseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7819a64b-9c03-4f66-a9e2-e9ac58c6935aSymplectic Elements at OxfordBioMed Central2015Abdulla, SAshley, EBassat, QBethell, DBjorkman, ABorrmann, SD'Alessandro, UDahal, PDay, NDiakite, MDjimde, ADondorp, ADuong, SEdstein, MDFairhurst, RFaiz, MFalade, CFlegg, JFogg, CGonzalez, RGreenwood, BGuerin, PGuthmann, JHamed, KHien, THtut, YJuma, ELim, PMartensson, AMayxay, MMokuolu, OMoreira, CNewton, PNoedl, HNosten, FOgutu, BOnyamboko, MOwusu-Agyei, SPhyo, APremji, ZPrice, RPukrittayakamee, SRamharter, MSagara, ISe, YSuon, SStepniewska, KWard, SAWhite, NWinstanley, PGrp, W<strong>Background:</strong> Artemisinin resistance in Plasmodium falciparum manifests as slow parasite clearance but this measure is also influenced by host immunity, initial parasite biomass and partner drug efficacy. This study collated data from clinical trials of artemisinin derivatives in falciparum malaria with frequent parasite counts to provide reference parasite clearance estimates stratified by location, treatment and time, to examine host factors affecting parasite clearance, and to assess the relationships between parasite clearance and risk of recrudescence during follow-up. <strong>Methods:</strong> Data from 24 studies, conducted from 1996 to 2013, with frequent parasite counts were pooled. Parasite clearance half-life (PC 1/2 ) was estimated using the WWARN Parasite Clearance Estimator. Random effects regression models accounting for study and site heterogeneity were used to explore factors affecting PC 1/2 and risk of recrudescence within areas with reported delayed parasite clearance (western Cambodia, western Thailand after 2000, southern Vietnam, southern Myanmar) and in all other areas where parasite populations are artemisinin sensitive. <strong>Results:</strong> PC 1/2 was estimated in 6975 patients, 3288 of whom also had treatment outcomes evaluate d during 28–63 days follow-up, with 93 (2.8 %) PCR-confirmed recrudescences. In areas with artemisinin-sensitive parasites, the median PC 1/2 following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of patients with PC 1/2 &gt;5 h from 0 to 10 %. Artesunate doses of 4 mg/kg/day decreased PC 1/2 by 8.1 % (95 % CI 3.2–12.6) compared to 2 mg/kg/day, except in populations with delayed parasite clearance. PC 1/2 was longer in children and in patients with fever or anaemia at enrolment. Long PC 1/2 (HR = 2.91, 95 % CI 1.95–4.34 for twofold increase, p &lt; 0.001) and high initial parasitaemia (HR = 2.23, 95 % CI 1.44–3.45 for tenfold increase, p &lt; 0.001) were associated independently with an increased risk of recrudescence. In western Cambodia, the region with the highest prevalence of artemisinin resistance, there was no evidence for increasing PC 1/2 since 2007. <strong>Conclusions:</strong> Several factors affect PC 1/2 . As substantial heterogeneity in parasite clearance exists between locations, early detection of artemisinin resistance requires reference PC 1/2 data. Studies with frequent parasite count measurements to characterize PC 1/2 should be encouraged. In western Cambodia, where PC 1/2 values are longest, there is no evidence for recent emergence of higher levels of artemisinin resistance.
spellingShingle Abdulla, S
Ashley, E
Bassat, Q
Bethell, D
Bjorkman, A
Borrmann, S
D'Alessandro, U
Dahal, P
Day, N
Diakite, M
Djimde, A
Dondorp, A
Duong, S
Edstein, MD
Fairhurst, R
Faiz, M
Falade, C
Flegg, J
Fogg, C
Gonzalez, R
Greenwood, B
Guerin, P
Guthmann, J
Hamed, K
Hien, T
Htut, Y
Juma, E
Lim, P
Martensson, A
Mayxay, M
Mokuolu, O
Moreira, C
Newton, P
Noedl, H
Nosten, F
Ogutu, B
Onyamboko, M
Owusu-Agyei, S
Phyo, A
Premji, Z
Price, R
Pukrittayakamee, S
Ramharter, M
Sagara, I
Se, Y
Suon, S
Stepniewska, K
Ward, SA
White, N
Winstanley, P
Grp, W
Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
title Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
title_full Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
title_fullStr Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
title_full_unstemmed Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
title_short Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis
title_sort baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative an individual patient data meta analysis
work_keys_str_mv AT abdullas baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT ashleye baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT bassatq baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT bethelld baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT bjorkmana baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT borrmanns baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT dalessandrou baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT dahalp baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT dayn baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT diakitem baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT djimdea baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT dondorpa baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT duongs baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT edsteinmd baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT fairhurstr baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT faizm baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT faladec baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT fleggj baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT foggc baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT gonzalezr baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT greenwoodb baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT guerinp baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT guthmannj baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT hamedk baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT hient baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT htuty baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT jumae baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT limp baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT martenssona baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT mayxaym baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT mokuoluo baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT moreirac baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT newtonp baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT noedlh baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT nostenf baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT ogutub baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT onyambokom baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT owusuagyeis baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT phyoa baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT premjiz baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT pricer baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT pukrittayakamees baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT ramharterm baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT sagarai baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT sey baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT suons baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT stepniewskak baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT wardsa baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT whiten baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT winstanleyp baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis
AT grpw baselinedataofparasiteclearanceinpatientswithfalciparummalariatreatedwithanartemisininderivativeanindividualpatientdatametaanalysis